Company Information

Kitov Pharmaceuticals (NASDAQ/TASE: KTOV) is an innovative biopharmaceutical company focused on late-stage drug development. Kitov’s pipeline currently features two combination drugs intended to treat osteoarthritis (OA) pain and hypertension (HTN) simultaneously. Lowering development risk and cost through streamlined regulatory approval of novel late-stage therapeutics, Kitov delivers rapid ROI while making a meaningful impact on people’s lives. 

Read More

Price Data
Recent News
Apr 3, 2017

Kitov Pharmaceuticals Holdings Ltd. (NASDAQ: KTOV, TASE: KTOV), an innovative biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has granted Kitov a waiver...

Mar 27, 2017

Combined treatment of TyrNovo's NT219 with targeted cancer drugs overcame acquired resistance of colon, lung, and head-and-neck cancers in PDX models Kitov Pharmaceuticals (NASDAQ and TASE: KTOV),...

Mar 8, 2017

Definitive agreement grants Kuhnil Pharmaceutical Co. Ltd. an exclusive license to manufacture and market KIT-302 in South Korea Transaction is Kitov's First License Agreement for KIT-302...

More >

print email